Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies.
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2014
At a glance
- Drugs NP 2 (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Diamyd Medical AB
- 03 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
- 04 Jul 2012 Positive results from this trial published in Annals of Neurology in 2011, according to a Diamyd media release.
- 12 Oct 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov record (NCT00804076).